India Pharma Sees Major Regulatory Changes in the Past Week

India’s pharmaceutical sector witnessed major regulatory changes between May 4 and May 9 as the Central Drugs Standard Control Organisation (CDSCO) rolled out stricter compliance measures and accelerated approval reforms.

The major regulatory changes covered drug approvals, pharmacovigilance reporting, clinical study permissions, and safety monitoring requirements for pharmaceutical companies operating in India.

The developments come at a time when India continues strengthening its position in the global pharmaceutical supply chain, accounting for nearly 20 percent of worldwide generic medicine exports and supplying drugs to more than 200 countries.

CDSCO Introduces 30-Day Deadline for Regulatory Responses

In one of the most significant policy changes of the week, CDSCO mandated that pharmaceutical companies must respond to regulatory queries within 30 days during the drug approval process.

Under the revised framework:

• Failure to respond within 30 days will result in automatic rejection of applications.
• Application fees will not be refunded.
• The rule applies to:
  • new drug applications,
  • clinical trial approvals,
  • biological products,
  • gene therapies,
  • and import registrations.

The regulator said the move was necessary to reduce growing application backlogs and eliminate incomplete submissions that delay approvals.

Industry analysts estimate CDSCO currently handles thousands of pending applications annually across drug imports, manufacturing permissions, and trial approvals. Regulatory officials believe stricter timelines could reduce approval bottlenecks by nearly 20–30 percent over the next year.

The reform is particularly important for India’s emerging biotech and biosimilar sectors, where companies frequently face long review cycles.

Also Read: Choosing the Right CDMO in India: A 2026 Compliance Guide

India Tightens Pharmacovigilance and Drug Safety Monitoring

CDSCO also intensified enforcement around pharmacovigilance compliance during the week.

Pharmaceutical manufacturers and importers were instructed to improve adverse event reporting timelines and strengthen post-marketing surveillance systems. Companies delaying Periodic Safety Update Reports (PSURs) could face regulatory action, including suspension of approvals.

The regulator noted that delayed safety reporting weakens drug monitoring systems and creates public health risks.

India’s pharmacovigilance market has grown rapidly over the last decade due to increasing exports to regulated markets such as:

• the United States,
• the European Union,
• Japan,
• and Canada.

According to industry estimates:

• India accounts for nearly 30 percent of global generic drug exports.
• More than 650 Indian manufacturing plants are approved by the USFDA.
• India has the largest number of USFDA-compliant plants outside the United States.

As global regulators increase scrutiny on drug safety and manufacturing quality, CDSCO appears to be aligning Indian reporting standards more closely with FDA and EMA expectations.

CDSCO Changes PSUR Reporting Calculation Rules

In another important compliance update, CDSCO clarified that Periodic Safety Update Reports must now be calculated from the actual market launch date of a product rather than from the date of approval.

The change affects:

• newly approved drugs,
• imported medicines,
• biologics,
• and specialty therapies.

Regulatory experts say the earlier system often created gaps between approval and commercial launch periods, resulting in inconsistent safety data collection.

The new rule is expected to improve:

• real-world adverse event tracking,
• post-commercialization monitoring,
• and risk assessment accuracy.

This reform is especially relevant as India witnesses rising approvals in:

• oncology,
• diabetes,
• obesity,
• biosimilars,
• and rare disease therapies.

India Announces Faster Drug Testing Approval System

India’s Health Ministry and CDSCO announced a major digital reform initiative designed to accelerate laboratory testing approvals for pharmaceutical products.

Beginning June 1, 2026:

• companies applying for No Objection Certificates (NOCs) for testing will receive immediate acknowledgments
• technical review will continue in parallel
• and approvals are expected to move substantially faster

Previously:

• companies often waited weeks for test permissions
• creating delays in product development and regulatory submissions

Officials believe the new system could significantly reduce:

• preclinical testing delays,
• manufacturing hold-ups,
• and export clearance timelines.

The reform aligns with India’s broader effort to position itself as a faster and more globally competitive pharmaceutical manufacturing hub.

Also Read: Pharma CDMOs in India & CDMO 2.0 Model: Detailed Review 2026

CDSCO Moves Toward “Prior Intimation” Clinical Study System

Another major policy shift announced during the week involved bioavailability and bioequivalence (BA/BE) studies.

Under the proposed “prior intimation” framework:

• companies may begin certain studies after notifying CDSCO,
• instead of waiting for formal written approvals.

The change is expected to:

• accelerate generic drug development
• reduce regulatory waiting periods
• improve competitiveness for Indian generic manufacturers.

India is already one of the world’s largest generic medicine suppliers:

• accounting for roughly 40 percent of generic demand in the United States by volume
• supplying medicines to more than 200 countries.

Industry groups have long argued that approval delays reduce India’s competitiveness against China and Eastern European manufacturing markets.

Regulatory Scrutiny Intensifies on Fixed-Dose Combination Drugs

CDSCO also increased scrutiny of fixed-dose combination (FDC) medicines, especially vitamin and mineral combinations lacking strong therapeutic evidence.

India has historically faced criticism for approving irrational FDC products that are not permitted in many developed markets.

Regulators are now reviewing:

• scientific justification,
• therapeutic effectiveness,
• and safety profiles of several combination products.

The crackdown could impact dozens of manufacturers operating in:

• nutraceuticals,
• over-the-counter products,
• and prescription combination therapies.

The Indian FDC market represents a multibillion-dollar segment of the pharmaceutical industry, making the review commercially significant.

Aurobindo Pharma Secures Major USFDA Approval

Among the biggest corporate regulatory developments of the week, Aurobindo Pharma received final USFDA approval for generic dapagliflozin and metformin hydrochloride extended-release tablets used in Type 2 diabetes treatment.

Key details:

• The product received 180-day exclusivity in the US market.
• The approval strengthens Aurobindo’s diabetes portfolio.
• The US diabetes drug market remains one of the fastest-growing global therapeutic segments.

India’s pharmaceutical exporters increasingly rely on complex generics and specialty drugs to improve margins amid pricing pressure in traditional generic markets.

Indian Companies Accelerate Semaglutide Expansion

The race to enter India’s rapidly expanding GLP-1 and obesity drug market accelerated during the week.

NATCO Pharma Receives CDSCO Approval

NATCO Pharma secured CDSCO approval for generic semaglutide injections in India.

Semaglutide demand has surged globally due to:

• rising obesity rates,
• increasing diabetes prevalence,
• and blockbuster success of GLP-1 therapies.

India currently has more than 101 million diabetes patients, according to International Diabetes Federation estimates, making it one of the world’s largest diabetes markets.

Glenmark Pharmaceuticals Launches GLIPIQ

Glenmark Pharmaceuticals launched GLIPIQ, its biosimilar semaglutide product, following regulatory approval.

The Indian GLP-1 segment is expected to become one of the country’s fastest-growing pharmaceutical categories over the next five years.

Analysts estimate the global obesity drug market could exceed $100 billion annually by the early 2030s, driving aggressive competition among Indian manufacturers.

India Pushes Regulatory Modernization

The week’s announcements collectively reflect India’s broader strategy to modernize its pharmaceutical regulatory system.

Current reform priorities include:

• digital approvals,
• faster licensing systems,
• risk-based reviews,
• harmonization with global standards,
• and reduced approval timelines.

The government is also working toward:

• stronger export competitiveness,
• increased biotech investment,
• and improved regulatory credibility in international markets.

Industry observers say India is attempting to balance two major goals simultaneously:

1. Faster approvals and innovation support.
2. Stronger compliance and patient safety oversight.

The success of these reforms could significantly influence India’s position in the global pharmaceutical supply chain over the next decade.